KRAS G12C MUTATION
Clinical trials for KRAS G12C MUTATION explained in plain language.
Never miss a new study
Get alerted when new KRAS G12C MUTATION trials appear
Sign up with your email to follow new studies for KRAS G12C MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo targets tough lung cancer mutation before surgery
Disease control Recruiting nowThis study tests a new treatment plan for people with a specific type of lung cancer (KRAS G12C mutation) that can be removed with surgery. Before surgery, patients receive a targeted drug (fulzerasib) for 6 weeks, then a break, followed by 3 cycles of immunotherapy (sintilimab) …
Matched conditions: KRAS G12C MUTATION
Phase: PHASE2 • Sponsor: Jianxing He • Aim: Disease control
Last updated May 26, 2026 04:54 UTC
-
New drug targets tough cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called KQB365 in adults with advanced solid tumors that have KRAS G12S or G12C mutations and no standard treatment options. The main goals are to find a safe dose and see if KQB365 alone or combined with other drugs (cetuximab or KQB198) ca…
Matched conditions: KRAS G12C MUTATION
Phase: PHASE1 • Sponsor: Kumquat Biosciences Inc. • Aim: Disease control
Last updated May 26, 2026 04:48 UTC